Company intelligence / Profile preview

Cranford Pharmaceuticals

Cranford, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Cranford Pharmaceuticals manufactured and held commercial rights for Inderal LA (propranolol ER capsules), used to treat hypertension, angina, migraine, and hypertrophic subaortic stenosis; in 2016, ANI Pharmaceuticals acquired the Inderal LA asset portfolio, which generated ~$30M in sales in 2015

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

ANI Pharmaceuticals (asset/portfolio acquisition, 2016)

Beyond the preview

Go deeper on Cranford Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cranford Pharmaceuticals.

Explore the full profile